The GlaxoSmithKline Plc's diabetes drug Avandia has been proved to be more harmful than its rival drug, an analysis done by U. S. government scientists has found.
It was revealed in an email forwarded by a Food and Drug Administration assessor that Avandia is associated with higher risks of heart troubles and deaths as compared to Takeda Pharmaceutical Co Ltd's competitor Actos.
Dr. David Graham, who studied the effects along with other Government staffers, revised the statistics of patients in the Medicare health insurance program and observed the older people who took either of the drugs. The team examined the data of nearly 230,000 Medicare patients and concluded that Avandia raised the risk of stroke by
27%, heart attack by 25% and death by 17%.
Mr. Graham is also known for having posed resistance to the now-withdrawn painkiller Vioxx.
After the present conclusion by Graham, it is being recommended that the drug should be removed from market as it is more harmful for heart as compared to the Actos.
Earlier also, a study conducted in 2007 doubted the drug and its cardiovascular effects.
The findings will provide more insight into the public meeting that is scheduled for next month, in order to discuss the health risks associated with the drug.
- Gentle Electrical Stimulation May Help in Improving Maths Skills
- Mutated BRCA1 Gene Increases Breast Cancer Risk
- Research Finds Huge Increase in Type-2 Diabetes, Under-40 Hardest Hit
- Step Forward in IVF Treatment in 30 Can Mount up Baby Production Three-times
- David Cameron Blamed for ‘Scaremongering’ Over Health Tourism